Study identifier:D9075C00001
ClinicalTrials.gov identifier:NCT05211895
EudraCT identifier:2021-004327-32
CTIS identifier:2023-506891-28-00
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab(AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
Non-small Cell Lung Cancer
Phase 3
No
Durvalumab, Domvanalimab
All
860
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Arcus Biosciences Inc
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm A: Durvalumab + Domvanalimab Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months | Drug: Durvalumab Durvalumab IV (Intravenous infusion) Drug: Domvanalimab Domvanalimab IV (Intravenous infusion) |
Active Comparator: Arm B: Durvalumab + Placebo Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months | Drug: Durvalumab Durvalumab IV (Intravenous infusion) Other: Placebo Placebo IV (Intravenous infusion) |